Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this bone marrow disorder.
Results from the ZN-c3-001, MAMMOTH, and DENALI trials demonstrated meaningful ORRs with azenosertib in platinum-resistant ovarian cancer.
The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.
In this issue of Blood, Ikeda and colleagues successfully demonstrated the utility of soluble B-cell maturation antigen (sBCMA) as a quantitative metric fo
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
January’s FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.
wednesday, february 26 continental breakfast 7-8 a.m. Keynote Session 4 8-8:30 a.m. Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California education…
Join the conversation with Fred Hutch Cancer Center. Enhance your knowledge and skills in the treatment of neuroendocrine tumors at our upcoming virtual event. Hosted…
Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to…
Cancer cases on rise in J&K; Over 12,000 cases being registered every year
